Skip to main
PACB
PACB logo

PACB Stock Forecast & Price Target

PACB Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Pacific Biosciences of California Inc. is positioned positively due to favorable placement and utilization trends for its Revio sequencing platform, indicating strong customer adoption that supports revenue growth. The company's management has expressed confidence in returning to growth this year, despite the challenges posed by the macroeconomic environment. Additionally, Pacific Biosciences has pursued strategic acquisitions, further strengthening its organic growth profile and suggesting potential for future market expansion.

Bears say

Pacific Biosciences of California Inc faces significant risks that could adversely impact its financial outlook, primarily stemming from stagnant utilization rates and weaker-than-expected demand for new instruments, which may jeopardize 2026 financial targets. Additionally, the company is challenged by demand weakness in China, which is anticipated to continue throughout 2023 and into 2024, potentially resulting in lost market share if competitors introduce superior products. Furthermore, reduced research budgets and tighter funding environments for academic and pharmaceutical institutions may constrain customers' purchasing power, directly affecting Pacific Biosciences' growth prospects.

PACB has been analyzed by 15 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pacific Biosciences of California (PACB) Forecast

Analysts have given PACB a Buy based on their latest research and market trends.

According to 15 analysts, PACB has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.37, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.37, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pacific Biosciences of California (PACB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.